Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diabetes Prevention Program Outcomes Study (DPPOS)
NCT00038727Phase 3Completed
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Jul 1996
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of liquid metformin (Aspargo Labs) in diabetes mellitus (DM), cancer and cardiovascular disease (CVD) (3 arms), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Primary endpoints: Number of Participants With Diabetes at 23 years, Prevalence of Aggregate Microvascular Complication at 2 years and 2 more. Started Jul 1996; status: completed.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
diabetes mellitus (DM)cancercardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT00038727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00038727.